GLP-1 Long Term Side Effects: What the 2026 Evidence Actually Shows
Published:
The honest answer in one paragraph
GLP-1 long term side effects are mostly digestive — nausea, vomiting, diarrhea, constipation, reflux, abdominal pain — and mostly happen during the first months or after a dose increase. The less common but more important risks to monitor over time are gallbladder disease, pancreatitis, dehydration that injures the kidneys, severe gut-motility events (gastroparesis, ileus, bowel obstruction), retinopathy worsening in people with diabetes, and a few newer signals — NAION (a sudden optic-nerve injury, now EU-labeled for semaglutide specifically), a musculoskeletal signal (osteoporosis, gout, osteomalacia) from a 2026 AAOS abstract, and lean-mass loss. Two widely-feared risks — suicidal ideation and population-wide thyroid cancer — have been substantially de-risked in 2025–2026.
🚨 Symptoms that mean ER same day — stop reading and get medical care
- Sudden vision change in one eye.
- Severe abdominal pain, especially radiating to your back, with or without vomiting.
- Persistent vomiting you can’t keep fluids through for 24+ hours.
- Severe constipation with abdominal swelling, vomiting, or no stool/gas.
- Severe right-upper-abdominal pain with fever, jaundice, or pale stools.
- Facial swelling, lip or tongue swelling, trouble breathing, severe rash.
- Severe low blood sugar — confusion, fainting, seizure — especially with insulin or a sulfonylurea.
- Fainting, confusion, or signs of severe dehydration.
If you came here worried about something specific
| Your worry | The bottom line |
|---|---|
| Nausea, vomiting, constipation, diarrhea that won’t quit | Common, especially during the first months and after dose increases. Persistent or severe symptoms past dose stabilization need a clinician review. |
| “Stomach paralysis” or bowel obstruction | Severe gastroparesis and ileus are real postmarketing reports. The Ozempic label was updated in January 2025 to warn against use in severe gastroparesis. They are not the typical experience. |
| Gallbladder issues / surgery | A label-listed risk on Wegovy, Zepbound, and others. Rapid weight loss in any form raises gallstone risk. |
| Pancreatitis | Rare on labels; the 2025 meta-analysis (66,232 patients across 62 RCTs) found a modest relative risk of 1.44 (95% CI 1.09–1.89). |
| Thyroid cancer | The boxed warning applies if you have a personal or family history of MTC or MEN 2. Large 2024–2025 cohorts (98,000+ users) do not show excess risk vs. comparator drugs. |
| Vision loss | NAION is now an EU-labeled “very rare” side effect of semaglutide (Ozempic, Rybelsus, Wegovy). Whether it applies class-wide is unsettled. Sudden vision change is an ER visit. |
| Mood / suicide warnings | The FDA requested removal of the suicidal-ideation warning on January 13, 2026, after finding no causal increase in 91 trials and 2.2 million users. |
| Muscle loss | Real, but in the same range as lifestyle weight loss — about 20–30% of total weight lost on average. Resistance training and protein (1.2–1.6 g/kg) are the standard mitigation. |
| What if I stop | Roughly two-thirds of weight is regained within a year on average per the STEP 1 extension. Stopping deserves a plan, not just an end date. |
2026 evidence snapshot
| Update | Status |
|---|---|
| FDA suicidal-ideation warning | Requested removal Jan. 13, 2026 (Saxenda, Wegovy, Zepbound) |
| EMA NAION conclusion | Semaglutide medicines, "very rare" — June 2025 |
| Foundayo (orforglipron) | FDA-approved Apr. 1, 2026; postmarketing safety requirements active |
| SURPASS-CVOT (tirzepatide) | Published Dec. 2025 — noninferior to dulaglutide for MACE |
| Compounded GLP-1 update | FDA proposed excluding semaglutide, tirzepatide, liraglutide from 503B bulks list, Apr. 30, 2026 |
| Last verified | May 9, 2026 |
What we verified for this page
Sources verified —
What Changed About GLP-1 Long Term Safety in 2025–2026
Three big things shifted in the last twelve months: the FDA formally asked drug makers to remove the suicidal-ideation warning from GLP-1 labels; the European Medicines Agency added NAION as a “very rare” side effect of semaglutide medicines specifically; and large multinational cohort studies found no substantially increased risk of thyroid cancer in GLP-1 users versus comparator drugs at 2–4 year follow-up. If a page you’re reading was written before January 2026 and still warns about suicidal thoughts as a class-wide GLP-1 effect, that page is out of date.
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound those drugs from bulk substances.
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for chronic weight management. The approval letter required postmarketing work on medullary thyroid carcinoma monitoring, pediatric long-term safety, pregnancy exposure, MACE, drug-induced liver injury, retained gastric contents/aspiration, and lactation. The FDA also requested 5 years of enhanced pharmacovigilance for serious unexpected drug-induced liver injury.
At the AAOS annual meeting, researchers reported higher incidence of osteoporosis (4.1% vs. 3.2%, RR 1.29), gout (7.4% vs. 6.6%, RR 1.12), and osteomalacia (0.2% vs. 0.1%, RR 2.55) in GLP-1 RA users versus controls. Drug-specificity within class and causality have not been established.
The FDA issued a Drug Safety Communication requesting removal of the suicidal-behavior-and-ideation warning language from GLP-1 labels (Saxenda, Wegovy, Zepbound). The agency reviewed 91 placebo-controlled trials covering 107,910 patients plus a Sentinel cohort study of 2,243,138 users; neither showed an increased risk versus comparators.
MDL 3163 (vision-loss/NAION cases) was consolidated in the Eastern District of Pennsylvania, separate from MDL 3094 (gastrointestinal injuries). In the same month, SURPASS-CVOT was published: tirzepatide was noninferior to dulaglutide for cardiovascular death, heart attack, or stroke in adults with type 2 diabetes and established atherosclerotic cardiovascular disease after a median 4-year follow-up.
The European Medicines Agency’s PRAC concluded NAION is a "very rare" side effect of semaglutide medicines specifically (Ozempic, Rybelsus, Wegovy). This is a semaglutide-specific regulatory finding; whether it applies class-wide remains unsettled.
The FDA-approved Ozempic label was updated to state it is "not recommended in patients with severe gastroparesis."
How We Grade GLP-1 Long Term Side Effects: The Four Evidence Buckets
When something gets called a “long-term side effect” of a GLP-1, it could be any of four things. The action you should take is different for each.
| Bucket | What it means | Example | What it tells you |
|---|---|---|---|
| Common trial side effect | Seen often in randomized clinical trials | Nausea, diarrhea, constipation, abdominal pain | Real, usually manageable, often dose-related. |
| Serious label warning | The FDA or EMA put it on the official label | Pancreatitis, gallbladder disease, acute kidney injury, thyroid C-cell tumors (boxed) | Uncommon to rare — but worth knowing the symptoms. |
| Postmarketing signal | Reported after approval; frequency uncertain | Ileus, severe gastroparesis, bowel obstruction | Real reports, but voluntary reporting can’t prove cause or rate. |
| Emerging observational signal | Association seen in real-world data; cause not settled | NAION, osteoporosis/gout/osteomalacia, hair thinning | Watch the evidence; ask your clinician if a personal risk factor lines up. |
There\u2019s also a fifth thing on the internet — Reddit and TikTok stories. We use those to find what real people are worried about, not to estimate medical risk. A fear is real. A medical claim needs more.
The GLP-1 Long Term Side Effects Evidence Matrix
Assembled from FDA labels for Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Rybelsus, and Foundayo (orforglipron) on DailyMed, current FDA safety communications, the EMA PRAC conclusion on NAION, and the most cited 2024–2026 peer-reviewed evidence — into one verified table you can scan in under two minutes.
Common trial side effects
| Side effect | What the evidence says | Reverses on discontinuation? | Action |
|---|---|---|---|
| Nausea, vomiting | Most common GLP-1 side effect class-wide. In the SELECT trial (semaglutide, median 39.8 months), 10.0% discontinued for GI symptoms vs. 2.0% on placebo. Most concentrated during dose escalation. | Yes, typically | If unmanaged after dose adjustment, call prescriber. ER if you can’t keep fluids down >24 hours. |
| Diarrhea, constipation | Both label-listed and common in trials. Reflects slowed gut motility. | Yes | Hydration, fiber, clinician-approved bowel plan. ER if severe constipation comes with vomiting, abdominal swelling, or no stool/gas. |
| Abdominal pain, reflux, burping | Common during titration and with high-fat meals. | Yes | Smaller meals, clinician review if persistent past dose stabilization. |
Serious label warnings
| Side effect | What the evidence says | Reverses on discontinuation? | Action |
|---|---|---|---|
| Cholelithiasis / cholecystitis (gallstones / inflamed gallbladder) | Listed on Wegovy and Zepbound labels. SELECT reported higher cholelithiasis rates in semaglutide vs. placebo. Rapid weight loss in any modality raises gallstone risk. | Not reliably; symptomatic gallstones often need medical or surgical management | ER for severe right-upper-abdominal pain, fever, yellowing eyes/skin, or pale stools. |
| Acute pancreatitis | Class-wide label warning. Wen et al. 2025 meta-analysis (62 RCTs, 66,232 patients): pancreatitis RR 1.44 (95% CI 1.09–1.89, p = 0.009). | Drug must be stopped; pancreatitis is its own treatment problem | ER for severe persistent abdominal pain, especially radiating to the back, with or without vomiting. |
| Acute kidney injury | Linked to dehydration from severe GI symptoms. Higher risk with CKD, diuretics, or older adults. | Often, yes — if caught early | ER if you can’t keep fluids down for 24+ hours, especially with diuretic, ACE-i/ARB, or known kidney disease. |
| Diabetic retinopathy worsening (in patients with diabetes) | SUSTAIN-6 (semaglutide, 2-year): 3.0% events vs. 1.8% placebo; absolute risk higher with pre-existing retinopathy (8.2% vs. 5.2%). Tied to rapid glucose improvement. | Damage to vision typically does not reverse, but progression slows | Baseline dilated eye exam if you have diabetes; ophthalmology follow-up per your specialist. |
| Boxed warning: medullary thyroid carcinoma in MTC/MEN 2 history | Class-wide boxed warning rooted in rodent C-cell tumor data — human relevance is unknown. Multinational cohorts (98,147+ users, 2024–2025) do not show excess thyroid cancer in the general user population. | N/A | Do not start a GLP-1 if you have a personal or family history of medullary thyroid carcinoma or MEN 2. |
| Aspiration during anesthesia / sedation | GLP-1s slow gastric emptying; residual food can remain at time of anesthesia. Rare aspiration reports prompted FDA to require additional postmarketing research. | N/A (procedure-time risk) | Tell your surgeon, anesthesiologist, dentist, and any procedure team you use a GLP-1 — every time. |
| Hypoglycemia (with insulin or sulfonylureas) | Class-wide label warning when combined with insulin or insulin secretagogues. | Yes, with dose adjustment | Ask your prescriber whether your insulin or sulfonylurea dose needs adjustment. |
Postmarketing signals
| Side effect | What the evidence says | Reverses on discontinuation? | Action |
|---|---|---|---|
| Severe gastroparesis (very slow stomach emptying) | Ozempic label updated January 2025: "not recommended in patients with severe gastroparesis." MDL 3094 had 3,546 pending actions as of the April 2026 JPML report. | Often, yes — but some persist for months | Persistent vomiting/early satiety past dose stabilization → call prescriber. ER for inability to keep fluids down. |
| Ileus (paralyzed bowel) | FDA added ileus to the Ozempic label in September 2023; already on Wegovy and Mounjaro. Rare but life-threatening. | Yes, with treatment | ER for severe abdominal pain with vomiting, distention, no bowel movement. |
Emerging observational signals
| Side effect | What the evidence says | Reverses on discontinuation? | Action |
|---|---|---|---|
| NAION (sudden, painless one-eye vision loss) — semaglutide-labeled in EU | EMA PRAC June 2025: classified as "very rare" side effect of semaglutide medicines specifically. 2024 JAMA Ophthalmology and 2026 JAMA Network Open cohorts both reported an association; absolute risk remained low. Class-wide applicability is unsettled. MDL 3163 consolidated December 2025. | Often permanent once vision loss occurs | Sudden vision change in one eye → ER same day. Do not wait. |
| Osteoporosis / gout / osteomalacia signal | AAOS 2026: osteoporosis RR 1.29 (4.1% vs. 3.2%); gout RR 1.12 (7.4% vs. 6.6%); osteomalacia RR 2.55 (0.2% vs. 0.1%). Drug-specificity and causality not established. | Bone disease is slowly reversible; osteomalacia is treatable | If you have other bone-loss risk factors (postmenopausal, low body weight, prior fractures, low vitamin D), discuss DEXA scan timing. |
| Lean-mass / muscle loss | Studies range 15–40% of total weight loss from lean tissue. 2026 systematic review of 20 studies: typically 70–80% fat / 20–30% lean — similar to lifestyle weight loss. SEMALEAN: handgrip strength improved 4.5 kg by month 12; sarcopenic-obesity prevalence fell from 49% to 33%. | Lean mass can be regained with training and nutrition | Resistance training 2–3×/week + protein 1.2–1.6 g/kg, especially over age 60. |
| Hair thinning | Tied to rapid weight loss (telogen effluvium). Wegovy label notes hair loss at higher rates than placebo. | Usually full recovery 6–12 months after weight stabilization or stopping | Not urgent; mention to your prescriber if persistent past 12 months. |
| Heart-rate increase | Small mean increase (~3 bpm) class-wide, with larger transient jumps in some users. | Yes | Persistently elevated resting heart rate or palpitations → call prescriber. |
| Suicidal ideation — DE-RISKED in 2026 | FDA Drug Safety Communication, January 13, 2026: requested removal of warning language from Saxenda, Wegovy, Zepbound. Based on 91 placebo-controlled trials (107,910 patients) and Sentinel cohort (2,243,138 users). | N/A (regulatory shift) | New or worsening depression deserves a clinician call regardless of medication. |
Common Digestive Side Effects: What’s Normal and When to Call
The most common GLP-1 long term side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, and decreased appetite — and they are most intense during the first weeks of use or after a dose increase. Many improve as your body adjusts; some persist; a smaller number are signs the dose, the medication, or your meals need to change.
Why they happen
GLP-1 medications slow gastric emptying — the speed at which food leaves your stomach. They also work on appetite signaling in the brain. Both effects are part of how the medications work. Both effects can also feel uncomfortable, especially when you eat too fast, eat too much in one sitting, or have a high-fat meal.
What “long-term” looks like for most people
GI side effects tend to peak during dose escalation and ease as the body adapts. SELECT — a multi-year cardiovascular outcomes trial of semaglutide in 17,604 adults with a median 39.8 months of follow-up — reported 10.0% discontinuation for GI symptoms in the semaglutide arm versus 2.0% in placebo, mostly during the first 20 weeks of dose escalation.
What helps
Smaller meals. Slower eating. Less fat per sitting. Stopping at fullness, not at “cleared plate.” Hydration. Fiber if your clinician approves it. Light movement. Do not invent your own dose schedule to chase fewer side effects. If a dose isn’t working for you, your prescriber can slow titration, hold a step, or switch products.
When to call your prescriber
- Symptoms that didn’t improve after a dose adjustment
- Vomiting after normal meals
- Constipation lasting more than a week
- Reflux that interrupts sleep
- Symptoms getting worse instead of better
When to go to the ER
- Inability to keep fluids down for 24+ hours
- Severe constipation paired with vomiting, abdominal swelling, or no bowel movements/gas
- Sudden severe abdominal pain
- Dehydration symptoms — fainting, confusion, very low urination — especially with diuretic or kidney disease
Can GLP-1s Cause Stomach Paralysis, Ileus, or Bowel Obstruction?
GLP-1 medications slow stomach emptying by design. Severe gastroparesis (where the stomach barely empties at all) and ileus (a paralyzed bowel) are real but uncommon postmarketing reports. The Ozempic label was updated in January 2025 to state it is “not recommended in patients with severe gastroparesis,” and ileus was added to the Ozempic label in September 2023 — both already listed on Wegovy and Mounjaro labels.
Why this concern exists
GLP-1 medications intentionally slow gastric emptying. In a small number of users, it appears to push past “delayed” into “very delayed” — the symptoms of severe gastroparesis: persistent vomiting of undigested food, severe early satiety, bloating. Ileus is different — it's a temporary paralysis of bowel muscle. Signs are severe abdominal pain, distention, vomiting, and inability to pass stool or gas. It is a medical emergency.
What the FDA labels say
- Ozempic label, updated January 2025: not recommended in patients with severe gastroparesis.
- Ozempic label, September 2023 update: ileus added to the postmarketing experience section.
- Wegovy and Mounjaro labels: similar postmarketing language for ileus and severe GI reactions.
The MDL picture
As of the April 1, 2026 JPML report, MDL 3094 (consolidated gastrointestinal-injury cases) had 3,546 pending actions in the Eastern District of Pennsylvania. The cases are in early discovery. Two things can be true at once: the injuries are real for the people who experienced them, and the existence of multidistrict litigation does not, by itself, prove the drug caused those injuries population-wide.
Who should ask the most questions before starting
GLP-1 Gallbladder Disease and Pancreatitis: What the Labels Actually Show
Gallbladder disease is a label-listed long-term risk, partly because rapid weight loss in any form raises gallstone risk. Pancreatitis is rarer but more dangerous; the most cited 2025 meta-analysis (62 RCTs, 66,232 patients) found a modestly increased relative risk of 1.44 for pancreatitis but no overall association with pancreatic cancer.
Gallbladder disease
Wegovy labeling reports cholelithiasis and cholecystitis at higher rates than placebo. The cause is partly the medication and partly the weight loss itself — any rapid weight loss raises gallstone risk because the gallbladder empties less efficiently when calorie intake drops.
ER if: severe right-upper-abdominal pain, fever, jaundice, pale stools, dark urine.
Pancreatitis
Wen et al. 2025 meta-analysis (62 RCTs, 66,232 patients): pancreatitis RR 1.44 (95% CI 1.09–1.89, p = 0.009). Pancreatic cancer: no overall significant association (RR 1.30, 95% CI 0.86–1.97). We treat pancreatic cancer as monitored/uncertain — not “disproven.”
ER if: severe persistent abdominal pain radiating to your back, with or without vomiting. Doesn't go away with position changes or OTC pain medicine.
Risk factors that warrant a longer conversation before starting
- Prior pancreatitis
- Heavy alcohol use
- Severe high triglycerides
- Gallstone disease
Can GLP-1s Damage Your Kidneys Long Term?
GLP-1 medications are not typically described as directly toxic to kidneys — but acute kidney injury can happen when severe GI side effects cause dehydration. Paradox: in adults with type 2 diabetes and chronic kidney disease, the FLOW trial found semaglutide reduced major kidney events by 24% over a median 3.4 years.
The dehydration pathway
Severe nausea, vomiting, or diarrhea → reduced fluid intake plus increased fluid loss → dehydration → reduced kidney perfusion → acute kidney injury. Reversible if caught early.
Higher-risk groups
- Chronic kidney disease (CKD) at baseline
- Older adults (over 65 especially)
- Already taking a diuretic, ACE inhibitor, or ARB
- Repeated vomiting or diarrhea episodes
- Aggressive calorie restriction or fasting protocols on top of the medication
The kidney protection finding (FLOW trial)
Perkovic et al. FLOW trial. Population enrolled was T2D + CKD.
GLP-1s and Your Eyes: Retinopathy and the NAION Question
Sudden vision change in one eye → ER same day. Do not wait.
NAION vision loss is often permanent. Time matters. This is not an appointment for next week.
Diabetic retinopathy worsening (in patients with diabetes only)
Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy. The Ozempic label cites the 2-year SUSTAIN-6 trial: retinopathy complications in 3.0% of the semaglutide group versus 1.8% on placebo. Risk was much higher in patients with pre-existing retinopathy at baseline (8.2% vs. 5.2%). This concern applies only to people with diabetes, not to people taking a GLP-1 only for weight management without diabetes.
Action: if you have diabetes, get a baseline dilated eye exam before or shortly after starting a GLP-1.
NAION — what the EMA decided in June 2025
NAION is a sudden, painless loss of vision in one eye, caused by reduced blood flow to the head of the optic nerve. In June 2025, the EMA PRAC concluded there was sufficient evidence to classify NAION as a “very rare” side effect of semaglutide medicines specifically — Ozempic, Rybelsus, Wegovy — and required the addition to EU product information. This is a regulatory finding for semaglutide, not for the whole GLP-1 class. Whether the finding applies class-wide is still being evaluated.
In the US, MDL 3163 (vision-injury cases) was consolidated in the Eastern District of Pennsylvania in December 2025.
| Drug | EU NAION label status | US NAION label status |
|---|---|---|
| Ozempic / Wegovy / Rybelsus (semaglutide) | NAION listed as "very rare" side effect (June 2025) | Postmarketing/observational evidence; no specific NAION addition to US labels at time of writing |
| Mounjaro / Zepbound (tirzepatide) | No NAION-specific labeling | No NAION-specific labeling |
| Foundayo (orforglipron) | Not yet marketed in EU | No NAION-specific labeling at approval |
| Liraglutide (Saxenda / Victoza) | No NAION-specific labeling | No NAION-specific labeling |
GLP-1s and Thyroid Cancer: What the Boxed Warning Means in 2026
The bright-line rule that hasn't changed
If you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), do not start a GLP-1. That part of the boxed warning is unchanged.
What the boxed warning is and isn't
A boxed warning is the FDA's strongest format. The warning was added because rodent studies showed long-term GLP-1 exposure caused thyroid C-cell hyperplasia and tumors in rats and mice. The label notes the human relevance is unknown.
What the human evidence shows (2024–2025)
| Study | GLP-1 users | Follow-up | Result | Limitation |
|---|---|---|---|---|
| Pasternak et al., BMJ 2024 (Scandinavian) | Multinational cohort | 3.9-yr mean | No substantial increase | Observational; residual confounding possible |
| Baxter et al., Thyroid 2025 (six-country) | 98,147 | 1.8–3.0 yr median | HR 0.81 (95% CI 0.59–1.12) — no increased risk | Short to medium follow-up |
Long-term oncology data beyond 5–7 years are still maturing. We won't claim cancer risk has been “disproven.” The data is reassuring at the time horizons studied.
GLP-1s and Mood, Depression, or Suicidal Thoughts: The FDA’s January 2026 Update
FDA update: January 13, 2026
The FDA issued a Drug Safety Communication requesting removal of the suicidal-behavior-and-ideation warning language from GLP-1 labels that carried it (Saxenda, Wegovy, Zepbound). Any older article warning about suicide risk as a GLP-1 class effect is now out of date.
| Status | What labels said / FDA action |
|---|---|
| Before Jan. 13, 2026 | Suicidal-behavior-and-ideation warning language appeared on Saxenda, Wegovy, and Zepbound labels |
| Jan. 13, 2026 | FDA Drug Safety Communication: requested removal of the warning language from affected labels |
| Evidence basis | 91 placebo-controlled trials (107,910 patients) + FDA Sentinel cohort study (2,243,138 users) — no increased risk vs. comparators |
| Live label status | Each manufacturer must update its label; the FDA "request" does not mean every label was revised on January 13 |
| What it doesn’t change | Personal mental-health symptoms still deserve clinical attention regardless of medication |
Muscle, Bone, and Body Composition Over Years on a GLP-1
Lean-mass loss on a GLP-1 is real but lands in roughly the same range as lifestyle-based weight loss — about 20–30% of total weight lost. The SEMALEAN trial showed lean mass declined initially then stabilized, while handgrip strength improved 4.5 kg and sarcopenic obesity prevalence fell from 49% to 33% over twelve months. Resistance training 2–3 times a week with adequate protein (1.2–1.6 g/kg) is the standard mitigation.
What the lean-mass data says
Studies of GLP-1 medications show lean mass typically accounts for about 20–30% of total weight lost, similar to lifestyle weight loss. Higher numbers (40%+) often include liver tissue reduction — a metabolic benefit, not a loss of skeletal muscle.
Who's at higher risk
- Adults over 60
- People who eat very little while on the medication
- People who don’t do resistance training
- People with pre-existing frailty or sarcopenia
- People losing weight rapidly (>1.5–2% of body weight per week sustained)
The standard mitigation
- 1Resistance training 2–3 times per week. Compound lifts beat cardio for muscle preservation.
- 2Protein 1.2–1.6 g per kg of body weight per day, distributed across meals (~25–40 g per meal).
- 3Adequate calories overall. Eating too little defeats the protein math.
- 4Don’t crash-diet on top of the medication. Aim for a moderate, sustainable deficit.
Bone, gout, and osteomalacia (AAOS 2026 signal)
| Outcome | GLP-1 users | Controls | Relative risk (95% CI) |
|---|---|---|---|
| Osteoporosis | 4.1% | 3.2% | 1.29 (1.22–1.36) |
| Gout | 7.4% | 6.6% | 1.12 (1.08–1.16) |
| Osteomalacia | 0.2% | 0.1% | 2.55 (1.83–3.55) |
Observational findings, not regulatory action. Whether they reflect the medication, the rapid weight loss, or the population is not yet settled.
Hair Thinning, “Ozempic Face,” and Other Body-Image Side Effects
Hair thinning on GLP-1 medications is real but usually temporary, tied to rapid weight loss rather than a unique GLP-1 mechanism. “Ozempic face” — facial fat loss creating a more aged appearance — is a consequence of fast weight loss in any modality, not a GLP-1-specific mechanism. Most cosmetic effects ease over 6–12 months as weight stabilizes.
Hair thinning (telogen effluvium)
A temporary hair-shedding pattern triggered by physical stress — including rapid weight loss, illness, surgery, or pregnancy. Typically starts 2–4 months after the trigger and resolves within 6–12 months. Wegovy labeling reports hair loss at higher rates than placebo. The mechanism is the rapid weight loss itself. What helps: enough protein, enough calories overall, iron and ferritin checked if persistent, patience.
Facial fat loss (“Ozempic face”)
Faces show weight loss faster than other parts of the body. Quick weight loss can leave a more hollowed appearance. This is not a mechanism unique to GLP-1 medications — it happens with bariatric surgery, severe illness, and very-low-calorie diets too. Slower weight loss reduces the visibility of the effect.
Skin laxity and stretch marks
Loose skin after major weight loss is a body-mechanics issue, not a side effect specific to a medication. The amount and pace of loss matter more than the drug.
GLP-1s Before Surgery, Anesthesia, or Any Procedure: Read This First
The only safe rule
Do not rely on a generic article — including this one — to decide when to hold your GLP-1 before a procedure. Tell every member of your procedure team you take a GLP-1, give them the medication name and last dose, and follow the protocol they give you.
Why this matters
Anesthesia and deep sedation rely on the assumption that your stomach is empty. GLP-1 medications slow gastric emptying. Even after a standard fasting period, residual food can remain in the stomach. If contents come back up while you are sedated and your airway reflexes are dulled, food can enter the lungs (aspiration), which is rare but serious. The FDA requires GLP-1 manufacturers to continue research on appropriate hold and fasting protocols.
Tell your procedure team — every one of them
Procedure-team handoff checklist (print this for your pre-op call)
Tirzepatide, Foundayo, and Oral Birth Control: The Warning Most Pages Bury
Tirzepatide (Mounjaro and Zepbound) labels warn that delayed gastric emptying can reduce the effectiveness of oral hormonal contraceptives. The label recommends switching to non-oral contraception or using a backup barrier method for 4 weeks after initiation and after each dose escalation. Foundayo (orforglipron) also carries an oral-birth-control warning, but its window is 30 days. Semaglutide labels do not currently include the same contraceptive-efficacy warning.
| Drug | Active ingredient | Oral contraceptive warning | Backup window |
|---|---|---|---|
| Mounjaro | Tirzepatide | Yes — labeled efficacy reduction | 4 weeks after initiation and after each dose escalation |
| Zepbound | Tirzepatide | Yes — labeled efficacy reduction | 4 weeks after initiation and after each dose escalation |
| Foundayo | Orforglipron | Yes — labeled efficacy reduction | 30 days after initiation and after each dose escalation |
| Ozempic / Wegovy / Rybelsus | Semaglutide | No equivalent warning currently | N/A |
| Saxenda / Victoza | Liraglutide | No equivalent warning currently | N/A |
See the perimenopause guide for why this warning matters especially for women in their 40s who may assume they are no longer fertile:
Best Tirzepatide for Perimenopause — oral HRT warning and contraception guidance →Are Long Term Side Effects Different on Ozempic, Wegovy, Mounjaro, Zepbound, or Foundayo?
Most GLP-1 long term side effects are class-wide. A few are drug-specific. You cannot directly compare side-effect percentages between drug labels — trials enroll different patients with different conditions and different doses.
| Drug | Active ingredient | Long-term CV trial | Drug-specific labeled finding |
|---|---|---|---|
| Ozempic / Wegovy / Rybelsus | Semaglutide | SELECT (4-yr); FLOW (CKD); SUSTAIN-6 | EU NAION label (June 2025); SUSTAIN-6-documented retinopathy worsening |
| Mounjaro / Zepbound | Tirzepatide | SURPASS-CVOT (published Dec. 2025: noninferior to dulaglutide) | Oral contraceptive efficacy warning (4-week window) |
| Saxenda / Victoza | Liraglutide | LEADER (CV benefit established) | Daily injection; longest track record |
| Trulicity | Dulaglutide | REWIND (CV benefit established) | — |
| Foundayo | Orforglipron | Postmarketing MACE study required | Oral non-peptide; oral contraceptive warning (30-day window); FDA-required postmarketing studies on MTC, pediatric safety, pregnancy, MACE, DILI, gastric contents/aspiration, lactation |
What this means for your decision
The difference that matters most for long-term safety is usually not which drug — it's which warnings line up with your specific history. Diabetic retinopathy + semaglutide → talk to your ophthalmologist. Oral contraception + tirzepatide or Foundayo → ask about the labeled window. Severe gastroparesis history + Ozempic → flagged on the label since January 2025. Family history of medullary thyroid carcinoma → don't start any GLP-1.
What Happens When You Stop a GLP-1: What Reverses, What Doesn't
| Trial / review | Drug | Average loss on treatment | Regain after stopping |
|---|---|---|---|
| STEP 1 extension (Wilding et al., DOM 2022) | Semaglutide 2.4 mg | 17.3% | ~11.6 percentage points (⅔ of loss) within 1 year; ~5.6% net retained at week 120; 48% maintained ≥5% loss |
| SURMOUNT-4 | Tirzepatide | — | ≥25% of lost weight within 1 year |
| BMJ-summarized 2026 review | Class | — | ~0.4 kg per month after stopping |
What reverses (weeks to months)
- GI symptoms — nausea, constipation, reflux, bloating
- Elevated heart rate
- Hair shedding (telogen effluvium)
- Fatigue
What partially reverses (months to a year)
- Weight loss — ~⅔ returns on average
- Glycemic control (A1C)
- Blood pressure improvements
- Cardiometabolic risk-factor improvements
What does NOT reverse
- NAION-related vision loss — often permanent
- Symptomatic gallstones
- Damage from a pancreatitis episode
- Structural retinopathy progression
What to ask before stopping
- "What’s our maintenance plan?"
- "Should we taper, pause, switch, or continue?"
- "How will we monitor my weight, blood sugar, blood pressure, and cardiometabolic markers off the medication?"
- "If I’m stopping because of cost or a side effect, is there a different medication or dose worth trying first?"
The Long-Term Benefits the Headlines Don't Talk About
A complete answer to “GLP-1 long term side effects” has to acknowledge the long-term benefits. For most eligible adults the overall benefit-risk profile is favorable on the benefit side. The studies below demonstrated benefit in specific populations — applying the result to a population the trial didn't enroll is a common mistake.
| Trial | Drug | Population enrolled | Headline finding |
|---|---|---|---|
| SELECT | Semaglutide 2.4 mg | Adults ≥45, BMI ≥27, established CVD, no diabetes | 20% MACE reduction; serious AEs lower than placebo (33.4% vs. 36.4%); median 39.8-mo follow-up |
| FLOW | Semaglutide 1.0 mg | Adults with type 2 diabetes + chronic kidney disease | 24% major kidney event reduction; 18% MACE reduction; 20% all-cause mortality reduction; median 3.4-yr follow-up |
| SURPASS-CVOT | Tirzepatide | Adults with T2D + established atherosclerotic CVD | Noninferior to dulaglutide for MACE; 12% vs. 13% primary events; median 4-yr follow-up |
| LEADER | Liraglutide | Adults with T2D at high CV risk | CV benefit established |
| REWIND | Dulaglutide | Adults with T2D at high CV risk | CV benefit established |
If your profile doesn't match any of the trial populations above, the absolute benefit may be smaller than the headlines suggest. Talk to your prescriber about which trial population most resembles your situation.
Your GLP-1 Symptom-to-Action Card (Print This for Your Next Appointment)
This is the asset most worth keeping. Print it. Save it. Bring it to your next appointment.
🚨 ER same day — get evaluated within hours, not days
- Sudden vision change in one eye (blurring, dark spot, total loss). NAION vision loss is often permanent.
- Severe persistent abdominal pain, especially radiating to your back, with or without vomiting. Possible pancreatitis.
- Persistent vomiting you can’t keep fluids through for 24+ hours, especially with diuretic, ACE-i/ARB, or known kidney disease.
- Severe constipation paired with abdominal swelling, vomiting, or no stool/gas — possible ileus or bowel obstruction.
- Severe right-upper-abdominal pain with fever, jaundice, or pale stools — possible cholecystitis.
- Facial swelling, lip or tongue swelling, trouble breathing, severe rash — possible allergic reaction.
- Severe low blood sugar symptoms — confusion, fainting, seizure — particularly if you also take insulin or a sulfonylurea.
- Fainting, severe dizziness, or signs of severe dehydration.
📞 Call your prescriber this week
- GI symptoms that haven’t improved after dose adjustment.
- Resting heart rate persistently elevated, or new palpitations.
- New fatigue or muscle weakness past initial titration.
- Right-upper-quadrant discomfort (without fever or jaundice).
- New eye symptoms that aren’t sudden but are unusual.
- Mood symptoms that are new or worsening.
- Repeated vomiting after normal meals past initial titration.
- Hair loss persisting past 6–9 months.
- Pregnancy, planning pregnancy, or contraception questions.
- Any upcoming surgery, anesthesia, endoscopy, or sedated dental work — call before the procedure.
📋 Bring up at your next routine visit
- Mild ongoing nausea managed with food adjustments.
- Cosmetic skin or facial changes from weight loss.
- Questions about DEXA scan timing (especially with bone-loss risk factors).
- Questions about resistance training or protein targets.
- Mild GI symptoms during titration.
- Questions about long-term plans — when to taper, switch, or continue.
How to Talk to Your Prescriber About Long Term Side Effects
The most useful clinician conversations are specific. Bring your medication name and dose, your reason for taking it, your current symptoms, your medical history, and the worry that drove you to ask. Generic “Is this safe?” gets a generic answer. Specific questions get specific answers.
The frame
“I’m on [medication] [dose] for [reason]. I have a question about [specific concern].”
About a specific symptom
“I’ve been having [specific symptom] for [time period]. It [got worse / didn’t change / partially improved] after my last dose adjustment. Is this likely the medication? What’s the next step?”
About a specific risk that lines up with your history
“I’m worried about [gastroparesis / pancreatitis / kidney injury / retinopathy / NAION / muscle loss / other]. I have [specific history] that I think is relevant. Does that change what I should watch for, or how often we should monitor?”
About surgery, anesthesia, or a procedure
“I have [procedure] scheduled on [date]. What’s your protocol for holding the GLP-1 before that day? How long should I fast?”
About contraception (tirzepatide or Foundayo)
“I take an oral contraceptive pill. Do I need a backup method during dose escalation? For how long?”
About stopping
“I’m thinking about stopping the medication because of [cost / side effect / weight goal reached / other]. What’s our maintenance plan? Is there a different option I should try first?”
What not to ask
“Is this drug safe?” — too vague. Your prescriber can’t answer that for the population; they can only answer it for you. Make it about you.
Who Needs Extra Monitoring on a GLP-1
If any of these apply, mention them before your first dose:
Medical history checklist
Medication checklist
How We Verified Everything on This Page
We built this page from primary sources — the FDA prescribing labels for each GLP-1 medication on DailyMed, FDA Drug Safety Communications and FDA-approved label updates, the European Medicines Agency PRAC conclusions, federal court records for the active multidistrict litigations, and the most cited 2024–2026 peer-reviewed evidence. We used Reddit and patient forums only to identify what real people are searching and worried about — never as evidence that a side effect is common, causal, or medically proven.
What we did not do
- Did not use Reddit, TikTok, or forum posts as medical evidence.
- Did not invent a medical reviewer. This article was built by The RX Index Editorial Team from primary sources.
- Did not claim cancer risk has been “disproven.” The evidence at the time horizons studied so far is reassuring; longer follow-up may sharpen the picture.
- Did not compare trial percentages across drugs as if the trials were head-to-head.
- Did not push you toward any particular product.
Last verified: . We re-check the FDA labels and Drug Safety Communications at least quarterly — and sooner after any major label update or safety communication.
GLP-1 Long Term Side Effects FAQ
- Are GLP-1 medications safe to take for the rest of my life?
- There is no lifetime-duration safety dataset for modern obesity-dose GLP-1 therapy yet. Available long-term datasets, including SELECT for semaglutide and longer clinical experience for older agents like liraglutide, are reassuring for the populations studied. Data beyond 5 to 7 years are still maturing. Continued use should be reviewed at every annual visit with your prescriber.
- Do GLP-1 long term side effects get worse the longer you take them?
- Most GI side effects are worst during dose escalation and improve over time. They do not generally worsen with chronic use at a stable dose. A few risks accrue with cumulative exposure, like gallstones tied to ongoing weight loss. The longest randomized trial available (SELECT, median 39.8 months) did not identify new long-term safety signals after the first year.
- Is NAION a side effect of all GLP-1s, or only some?
- As of the European Medicines Agency PRAC’s June 2025 conclusion, NAION is labeled as a “very rare” side effect of semaglutide medicines specifically (Ozempic, Rybelsus, Wegovy). Tirzepatide, orforglipron, and other GLP-1s do not carry NAION-specific labeling at this time. Whether the finding applies class-wide is still being evaluated.
- Did the FDA request removal of the suicide warning from GLP-1 weight-loss labels?
- Yes. On January 13, 2026, the FDA requested removal of suicidal-behavior-and-ideation warning language from the GLP-1 labels that carried it: Saxenda, Wegovy, and Zepbound. The decision was based on 91 placebo-controlled trials covering 107,910 patients plus a Sentinel cohort study of 2,243,138 users, neither showing an increased risk versus comparators. Each manufacturer must update its label following the request.
- How much muscle do you actually lose on a GLP-1?
- Most studies show 20% to 30% of total weight lost comes from lean body mass — similar to lifestyle weight loss. Higher numbers (40%+) often include non-muscle lean tissue like liver volume reduction. Resistance training 2 to 3 times a week and 1.2 to 1.6 grams of protein per kilogram of body weight per day is the standard preservation strategy.
- What happens to your body when you stop a GLP-1 long term?
- Most reversible side effects (GI symptoms, hair shedding, heart-rate change, fatigue) resolve over weeks to months. Weight regain is well-documented — about two-thirds of loss regained within a year per the STEP 1 extension; tirzepatide users in SURMOUNT-4 regained at least 25% of lost weight within a year. Cardiometabolic benefits also fade. Restarting after a break should be coordinated with your prescriber.
- Is there a long-term cancer risk from GLP-1 medications?
- The 2025 randomized-trial meta-analysis (Wen et al.) found no overall pancreatic cancer association (RR 1.30, 95% CI 0.86–1.97), with a small significant association in the background-medication subgroup — we treat pancreatic cancer as monitored/uncertain, not “disproven.” Multinational thyroid cancer cohorts (Baxter et al. 2025, 98,147 users; Pasternak et al. 2024) showed no substantial increase in thyroid cancer in the general user population. The boxed warning remains real for people with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Should I worry about gastroparesis if I’ve been on Ozempic for over a year?
- Severe gastroparesis is rare but documented. As of January 2025, the Ozempic label states it is “not recommended in patients with severe gastroparesis.” If you have persistent vomiting, severe early satiety, or symptoms that don’t resolve after dose adjustment, contact your prescriber. New persistent vomiting you can’t manage with fluids is an ER visit.
- Will my long-term side effects be different on a compounded GLP-1 versus an FDA-approved one?
- Compounded GLP-1s vary widely in formulation, sterility, and dosing accuracy. The FDA has documented counterfeits, wrong active ingredients, and dosing errors causing hospitalization in this category. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound those drugs from bulk substances. The long-term safety conclusions on this page are based on FDA-approved products. If you’re using a compounded product, the risk profile is not the same.
- How often should my prescriber check on long term GLP-1 side effects?
- A reasonable cadence is a follow-up visit 3–6 months after dose stabilization and at minimum annually thereafter, with labs to monitor kidney function, A1C if applicable, and lipids. Patients with diabetic retinopathy, prior pancreatitis, gallbladder symptoms, or musculoskeletal risk factors may need more frequent monitoring. Your prescriber will set the right schedule for you.
- Do GLP-1s affect oral birth control?
- Tirzepatide labels (Mounjaro and Zepbound) warn that delayed gastric emptying may reduce oral hormonal contraceptive efficacy and recommend a non-oral method or barrier method for 4 weeks after initiation and after each dose escalation. Foundayo (orforglipron) carries the same type of warning with a 30-day window. Semaglutide labels do not currently include the same contraceptive-efficacy warning.
- Should I stop a GLP-1 before surgery?
- Don’t rely on a generic internet rule. Tell your surgeon, anesthesiologist, dentist, or proceduralist that you take a GLP-1 — give them the medication name and last dose — and follow their current protocol. Current multi-society guidance says most patients can continue GLP-1 drugs before elective surgery, while higher-risk patients may need a liquid-diet plan, anesthesia-plan adjustment, or procedure delay.
Final Word
If you came here scared by a headline, a friend, a TikTok, or a symptom you can't explain — here's the version we'd give a family member:
For most eligible adults on an FDA-approved GLP-1, prescribed by a licensed clinician and dispensed through a legitimate pharmacy, the long-term side-effect profile looks like this — most of what you'll feel is digestive and worst during dose changes; a smaller list of label-warned risks deserves real attention if symptoms appear; a smaller still list of postmarketing and observational signals is being watched as the data accrues; two long-feared risks (suicidal ideation and population-wide thyroid cancer) have been substantially de-risked in the last twelve months; and a real, calm conversation with your prescriber — using the Symptom-to-Action Card above and your own history — does more for your long-term safety than any single article on the internet.
Print the card. Bring it to your appointment. Update what you know when the evidence updates. We update this page when the evidence updates.